AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28684614 — intervention group
Group type: EXPERIMENTAL
Intervention: Qred (200 mg/d)
Number of subjects: 36
Study 25564194 — intervention group
Group type: EXPERIMENTAL
Intervention: Williams LifeSkills Training (WLST)
Number of subjects: 66
Study 25564194 — intervention group
Group type: COMPARATOR
Intervention: Control (usual intervention)
Number of subjects: 66
Study 23137063 — intervention group
Group type: COMPARATOR
Intervention: Pulsed-dye laser (PDL) treatment
Number of subjects: 15
Study 23137063 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) treatment
Number of subjects: 15
Study 21523262 — intervention group
Group type: EXPERIMENTAL
Intervention: WPC preparation
Number of subjects: 30
Study 21523262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19257821 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (15 mg once per week for patients <40 kg; 30 mg once per week for patients >40 kg)
Number of subjects: 26
Study 19257821 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate
Number of subjects: 26
Study 19257821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17101701 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable appliance with a palatal crib associated with high-pull chin cup therapy for 12 months
Number of subjects: 30
Study 17101701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 16197750 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD only
Number of subjects: 75
Study 16197750 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD and lecture
Number of subjects: 75
Study 16197750 — intervention group
Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 75
Study 11315834 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg)
Number of subjects: 10
Study 11315834 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (0.3 mg)
Number of subjects: 10
Study 9223026 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (250 mg (3 mmol).(kg body weight)‐1)
Number of subjects: 7
Study 9223026 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7
Study 8192551 — intervention group
Group type: EXPERIMENTAL
Intervention: L-365,260 (50 mg)
Number of subjects: 29
Study 8192551 — intervention group
Group type: EXPERIMENTAL
Intervention: L-365,260 (10 mg)
Number of subjects: 29
Study 8192551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 3359905 — intervention group
Group type: EXPERIMENTAL
Intervention: vodka (37.5 ml) in tomato juice
Number of subjects: 10
Study 3359905 — intervention group
Group type: COMPARATOR
Intervention: tomato juice alone
Number of subjects: 10
Study 31944276 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg/d
Number of subjects: 979
Study 31944276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 979
Study 31489825 — intervention group
Group type: EXPERIMENTAL
Intervention: Autistic children
Number of subjects: 407
Study 31489825 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 407
Study 31489825 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 407
Study 28179454 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 10 mg/kg i.v. every 2 or 3 weeks until disease progression
Number of subjects: 1374
Study 28179454 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 2 or 10 mg/kg i.v. every 3 weeks
Number of subjects: 1374
Study 28179454 — intervention group
Group type: COMPARATOR
Intervention: ipilimumab 3 mg/kg every 3 weeks for up to four doses
Number of subjects: 1374
Study 28179454 — intervention group
Group type: COMPARATOR
Intervention: investigator's choice of chemotherapy
Number of subjects: 1374
Study 25984611 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 % ropivacaine infiltrated at the trocar insertion sites and in the gallbladder fossa
Number of subjects: 50
Study 25984611 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dipyrone
Number of subjects: 50
Study 25984611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 23494213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment program
Number of subjects: 89
Study 23494213 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 89
Study 23494213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 89
Study 21242556 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based clinical decision support system
Number of subjects: 2556
Study 18065809 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg single dose)
Number of subjects: 39
Study 18065809 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily for 4 weeks)
Number of subjects: 39
Study 18065809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 17359691 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaundice-reducing group (UPTBD and ENBD)
Number of subjects: 183
Study 17359691 — intervention group
Group type: COMPARATOR
Intervention: Non-reducing group (general pre-operation routine preparation)
Number of subjects: 183
Study 14598035 — intervention group
Group type: EXPERIMENTAL
Intervention: Wender Utah Rating Scale short form (WURS-k)
Number of subjects: 63
Study 14598035 — intervention group
Group type: EXPERIMENTAL
Intervention: WURS-k total score
Number of subjects: 63
Study 14598035 — intervention group
Group type: EXPERIMENTAL
Intervention: WURS-k individual factors
Number of subjects: 63
Study 14598035 — intervention group
Group type: EXPERIMENTAL
Intervention: Eysenck's Impulsivity Questionnaire (EIQ)
Number of subjects: 63
Study 14598035 — intervention group
Group type: EXPERIMENTAL
Intervention: WURS-k
Number of subjects: 63
Study 10971238 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone (n=120, group A, loading dose 40-60 mg IV, followed by repeated doses of 20 mg)
Number of subjects: 239
Study 10971238 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus midazolam (n=119, group B, initial midazolam dose of 2.5-3.5 mg IV, followed by repeated doses of 20 mg of propofol)
Number of subjects: 239
Study 8774280 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal 3-D ultrasound evaluation
Number of subjects: 42
Study 1310922 — intervention group
Group type: EXPERIMENTAL
Intervention: L-(−)-Ephedrine hydrochloride (50 mg three times a day)
Number of subjects: 10
Study 1310922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31479355 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving to Opportunity for Fair Housing Demonstration Program (intervention group)
Number of subjects: 4600
Study 31479355 — intervention group
Group type: COMPARATOR
Intervention: Control group (households not receiving the intervention)
Number of subjects: 4600
Study 30106185 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVL) group, N = 96
Number of subjects: 361
Study 30106185 — intervention group
Group type: COMPARATOR
Intervention: Calcineurin Inhibition (CNI) group (CsA), N = 89
Number of subjects: 361
Study 30106185 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS group, N = 39
Number of subjects: 361
Study 26672637 — intervention group
Group type: EXPERIMENTAL
Intervention: Somavaratan 1.15 mg/kg weekly
Number of subjects: 68
Study 26672637 — intervention group
Group type: EXPERIMENTAL
Intervention: Somavaratan 2.5 mg/kg twice monthly
Number of subjects: 68
Study 26672637 — intervention group
Group type: EXPERIMENTAL
Intervention: Somavaratan 5.0 mg/kg monthly
Number of subjects: 68
Study 24074143 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 50/250 via Rotahaler
Number of subjects: 60
Study 24074143 — intervention group
Group type: COMPARATOR
Intervention: SFC 50/250 via Diskus
Number of subjects: 60
Study 24074143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both inhalers
Number of subjects: 60
Study 22497929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital stroke treatment in a mobile stroke unit (MSU)
Number of subjects: 100
Study 22497929 — intervention group
Group type: COMPARATOR
Intervention: Optimised conventional hospital-based stroke treatment (control group)
Number of subjects: 100
Study 20155247 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU vitamin D(3)/day (intervention group)
Number of subjects: 221
Study 20155247 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 221
Study 17649769 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 0
Study 11703549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse specialist model
Number of subjects: 99
Study 11703549 — intervention group
Group type: COMPARATOR
Intervention: Traditional care model
Number of subjects: 99
Study 9041371 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 13
Study 9041371 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic clamping with constant insulin levels
Number of subjects: 13
Study 8105678 — intervention group
Group type: COMPARATOR
Intervention: 3-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Number of subjects: 37
Study 8105678 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day treatment with amoxicillin and clavulanate potassium (20 mg/kg per day of amoxicillin and 5 mg/kg per day of clavulanate potassium in three divided doses)
Number of subjects: 37
Study 8105678 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections involving adhesin-negative isolates
Number of subjects: 37
Study 8105678 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections involving adhesin-positive isolates
Number of subjects: 37
Study 3690939 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin, 1.0 mg intravenously
Number of subjects: 8
Study 3690939 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously
Number of subjects: 8
Study 31167551 — intervention group
Group type: EXPERIMENTAL
Intervention: psychosexual intervention
Number of subjects: 46
Study 29683921 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 54
Study 29683921 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 54
Study 28686823 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure plus methylene blue (IE + MB)
Number of subjects: 42
Study 28686823 — intervention group
Group type: COMPARATOR
Intervention: Imaginal exposure plus placebo (IE + PBO)
Number of subjects: 42
Study 28686823 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL/standard PE)
Number of subjects: 42
Study 25705798 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine HCl
Number of subjects: 52
Study 25705798 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 52
Study 23199095 — intervention group
Group type: EXPERIMENTAL
Intervention: RMT
Number of subjects: 39
Study 23199095 — intervention group
Group type: EXPERIMENTAL
Intervention: PMT
Number of subjects: 39
Study 23199095 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 39
Study 21036510 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach case management (OCM)
Number of subjects: 230
Study 21036510 — intervention group
Group type: COMPARATOR
Intervention: Passive referral
Number of subjects: 230
Study 18496183 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (40, 80, 120, 160, and 200 microg/kg)
Number of subjects: 0
Study 18496183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18496183 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (combined treatment group)
Number of subjects: 0
Study 18496183 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa (80-200 microg/kg)
Number of subjects: 0
Study 16541277 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fibre diet
Number of subjects: 500
Study 16541277 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-fibre diet
Number of subjects: 500
Study 16541277 — intervention group
Group type: COMPARATOR
Intervention: Low-fat/high-fibre diet
Number of subjects: 500
Study 14712893 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents (specific agents not mentioned)
Number of subjects: 0
Study 14712893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of antiplatelet agents (specific agents not mentioned)
Number of subjects: 0
Study 10925615 — intervention group
Group type: EXPERIMENTAL
Intervention: Single radiation dose of 8 Gy
Number of subjects: 0
Study 10925615 — intervention group
Group type: COMPARATOR
Intervention: Ten treatments of 3 Gy delivered over two weeks
Number of subjects: 0
Study 8922218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid infusion pump pressures maintained below women's mean arterial pressures (MAPs)
Number of subjects: 40
Study 8922218 — intervention group
Group type: COMPARATOR
Intervention: Fluid infusion pump pressures set at random
Number of subjects: 40
Study 1565267 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg) given three times before surgery and three times after surgery
Number of subjects: 138
Study 1565267 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thymopentin)
Number of subjects: 138
Study 30064582 — intervention group
Group type: EXPERIMENTAL
Intervention: SIGNOUT? method
Number of subjects: 0
Study 30064582 — intervention group
Group type: EXPERIMENTAL
Intervention: 9Ds method
Number of subjects: 0
Study 30064582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no method used)
Number of subjects: 0
Study 26620092 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 203
Study 26620092 — intervention group
Group type: COMPARATOR
Intervention: General practitioner (GP) care
Number of subjects: 203
Study 25059308 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR-R (MPR plus lenalidomide maintenance)
Number of subjects: 0
Study 25059308 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan and prednisone)
Number of subjects: 0
Study 25059308 — intervention group
Group type: COMPARATOR
Intervention: MPR (MP plus lenalidomide)
Number of subjects: 0
Study 22626675 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg of antigen with half the standard dose of MF59 adjuvant
Number of subjects: 812
Study 22626675 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg of antigen with a full dose of MF59 adjuvant
Number of subjects: 812
Study 22626675 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted vaccine containing 15 μg of antigen
Number of subjects: 812
Study 22626675 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg adjuvanted formulation
Number of subjects: 812
Study 22626675 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg adjuvanted formulation
Number of subjects: 812
Study 22626675 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with seasonal influenza vaccine
Number of subjects: 812
Study 20385711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg bid
Number of subjects: 1258
Study 20385711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1258
Study 20385711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 1258
Study 18166097 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy (scaling and root planing)
Number of subjects: 0
Study 18166097 — intervention group
Group type: COMPARATOR
Intervention: Community dental care (control)
Number of subjects: 0
Study 17149989 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation (201 mg of caffeine per day)
Number of subjects: 36
Study 17149989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 pills per day)
Number of subjects: 36
Study 17149989 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine supplementation
Number of subjects: 36
Study 17149989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 14976565 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC4 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 4 days)
Number of subjects: 70
Study 14976565 — intervention group
Group type: EXPERIMENTAL
Intervention: RAC7 (rabeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 70
Study 14976565 — intervention group
Group type: COMPARATOR
Intervention: OAC7 (omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for 7 days)
Number of subjects: 70
Study 10601778 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre‐optic transillumination (FOTI)
Number of subjects: 182
Study 10601778 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective temporary tooth separation (ETTS)
Number of subjects: 182
Study 10601778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic caries measurement (ECM)
Number of subjects: 182
Study 10601778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical visual examination at the D(1) threshold
Number of subjects: 182
Study 8785151 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflation of the LMA cuff to a pressure of 22 mm Hg
Number of subjects: 56
Study 8785151 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete cuff deflation
Number of subjects: 56
Study 8785151 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed LMA cuff
Number of subjects: 56
Study 1329159 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 60
Study 1329159 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 60
Study 1329159 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 12 mg
Number of subjects: 60
Study 1329159 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 60
Study 1329159 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 60
Study 1329159 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 60
Study 2931968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluosol‐DA 20% (FL)
Number of subjects: 34
Study 2931968 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 34
Study 30790440 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise programme with vibration training
Number of subjects: 61
Study 30790440 — intervention group
Group type: COMPARATOR
Intervention: Eccentric exercise programme combined with cryotherapy
Number of subjects: 61
Study 29059600 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 15.0 mg/kg (T3)
Number of subjects: 100
Study 29059600 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 30.0 mg/kg (T4)
Number of subjects: 100
Study 29059600 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 0.3 mg/kg (T1)
Number of subjects: 100
Study 29059600 — intervention group
Group type: EXPERIMENTAL
Intervention: 17alpha‐methyltestosterone (MT) at 3.0 mg/kg (T2)
Number of subjects: 100
Study 29059600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormone)
Number of subjects: 100
Study 26574050 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (60 minutes general fitness class, 40 minutes endurance training/aerobic, 20 minutes strength training and stretching/relaxation, performed at least twice per week for a minimum of 12 weeks)
Number of subjects: 105
Study 26574050 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (≥ 24 sessions)
Number of subjects: 105
Study 26574050 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 26574050 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (≥ 19 sessions, n=21 or ≥ 24 sessions, n=14)
Number of subjects: 105
Study 26574050 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 105
Study 24693953 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic optimization of AV and VV delay
Number of subjects: 400
Study 24693953 — intervention group
Group type: COMPARATOR
Intervention: Haemodynamic optimization using non‐invasive blood pressure monitoring
Number of subjects: 400
Study 22358123 — intervention group
Group type: EXPERIMENTAL
Intervention: ramosetron 0.3 mg
Number of subjects: 120
Study 22358123 — intervention group
Group type: COMPARATOR
Intervention: dexamethasone 8 mg
Number of subjects: 120
Study 22358123 — intervention group
Group type: EXPERIMENTAL
Intervention: ramosetron 0.3 mg combined with dexamethasone 8 mg
Number of subjects: 120
Study 19037777 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated proprioception assessment using a magnetic motion tracking system
Number of subjects: 22
Study 19037777 — intervention group
Group type: COMPARATOR
Intervention: Control group (neurologically intact subjects)
Number of subjects: 22
Study 19037777 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated proprioception assessment
Number of subjects: 22
Study 19037777 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 15983182 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric-only resistance training
Number of subjects: 30
Study 15983182 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic concentric-only resistance training
Number of subjects: 30
Study 15983182 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric-only resistance training
Number of subjects: 30
Study 12463731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide (120 mg, 10 min before meals for 4 days) + Warfarin (30 mg on the second day)
Number of subjects: 12
Study 12463731 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (30 mg) alone
Number of subjects: 12
Study 12463731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide + Warfarin
Number of subjects: 12
Study 12463731 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 12
Study 10513507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 2,400 mg/day for 28 days
Number of subjects: 0
Study 10513507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10513507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0